Please assess the completion status of the following clinical trial:

Trial Title: A Study to Test 2 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Healthy Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~* Healthy infants 6-12 or 11-17 weeks of age at the time of dose 1 whose parent/guardian sign a written informed consent and whose parents/guardians can and will comply with the requirements of the protocol.~Exclusion criteria:~* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine or placebo, or planned use during the study period.~* Chronic administration of immunosuppressants or other immune-modifying drugs since birth.~* Child is unlikely to remain in the study area during study.~* Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection.~* History of allergic disease or reaction likely to be exacerbated by any component of the vaccine.~* Administration of immunoglobulins and/or blood products since birth or planned administration during the study period.~* Any clinically significant history of chronic gastrointestinal disease including any uncorrected congenital malformation of the gastrointestinal tract or other serious medical condition as determined by the investigator.~* First or second degree of consanguinity of parents.

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 17 Weeks
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).